Literature DB >> 6932916

The response of a human tumour xenograft to chemotherapy: intrinsic variation between tumours and its significance in planning experiments.

H M Warenius, L S Freedman, N M Bleehen.   

Abstract

The HT29R human colon adenocarcinoma cell line has been used to investigate the problem of inter-tumour variability in the xenograft system and how this may affect the planning of chemotherapy experiments. Subcutaneous inoculation of 10(6) in vitro cells into immuno-suppressed mice yielded an 80% take rate of moderately poorly differentiated, mucin-secreting tumours with a mean doubling time of 6 days. Statistical estimates from experiments with this system demonstrated that whereas a delay of one doubling time in treated compared with control groups could be detected with relatively small animal numbers, 3 to 4 times as many animals were needed to detect a delay of half a doubling time. The use of 2 tumours per animal yielded the same results as one tumour per animal but reduced the number of animals needed to achieve the same degree of statistical significance.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6932916      PMCID: PMC2149238     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  8 in total

1.  Human tumours grown in mice.

Authors:  J E Castro
Journal:  Nat New Biol       Date:  1972-09-20

2.  Heterotransplantation of human adenocarcinomas of the colon and rectum to the mouse mutant Nude. A study of nine consecutive transplantations.

Authors:  C O Povlsen; J Rygaard
Journal:  Acta Pathol Microbiol Scand A       Date:  1971

3.  The therapeutic response of three human tumor lines maintained in immune-suppressed mice.

Authors:  L Kopper; G G Steel
Journal:  Cancer Res       Date:  1975-10       Impact factor: 12.701

4.  Immunohistology of the antigenic pattern of a continuous cell line from a human colon tumor.

Authors:  S von Kleist; E Chany; P Burtin; M King; J Fogh
Journal:  J Natl Cancer Inst       Date:  1975-09       Impact factor: 13.506

5.  Transplantation of human tumors in nude mice.

Authors:  Y Shimosato; T Kameya; K Nagai; S Hirohashi; T Koide; H Hayashi; T Nomura
Journal:  J Natl Cancer Inst       Date:  1976-06       Impact factor: 13.506

6.  Improved immune-suppression techniques for the exongrafting of human tumours.

Authors:  G G Steel; V D Courtenay; A Y Rostom
Journal:  Br J Cancer       Date:  1978-02       Impact factor: 7.640

7.  Maintenance of biological and biochemical characteristics of human colorectal tumours during serial passage in immune-deprived mice.

Authors:  J A Houghton; D M Taylor
Journal:  Br J Cancer       Date:  1978-02       Impact factor: 7.640

8.  Growth characteristics of human colorectal tumours during serial passage in immune-deprived mice.

Authors:  J A Houghton; D M Taylor
Journal:  Br J Cancer       Date:  1978-02       Impact factor: 7.640

  8 in total
  6 in total

1.  CB 1954 revisited. II. Toxicity and antitumour activity.

Authors:  P Workman; J E Morgan; K Talbot; K A Wright; J Donaldson; P R Twentyman
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  CB 1954 revisited. I. Disposition kinetics and metabolism.

Authors:  P Workman; R A White; K Talbot
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Metoclopramide enhances the effect of cisplatin on xenografted squamous cell carcinoma of the head and neck.

Authors:  E Kjellén; J Wennerberg; R Pero
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

4.  Ovarian tumour xenografts in the study of the biology of human epithelial ovarian cancer.

Authors:  M L Friedlander; P Russell; I W Taylor; M H Tattersall
Journal:  Br J Cancer       Date:  1985-03       Impact factor: 7.640

5.  Response of a high-glucuronidase human tumour xenograft to aniline mustard.

Authors:  H M Warenius; P Workman; N M Bleehen
Journal:  Br J Cancer       Date:  1982-01       Impact factor: 7.640

6.  The chemotherapeutic response of a murine (VM) model of human glioma.

Authors:  R Bradford; J L Darling; D G Thomas
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.